文献速递肿瘤 PET/CT核素与放射性配体治疗

朗格汉斯胰岛α细胞中成纤维细胞活化蛋白的表达及其对FAPI放射性药物应用的启示

FAP expression in alpha cells of Langherhans insulae-implications for FAPI radiopharmaceuticals' use.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-05-04

该回顾性研究纳入2家机构共40例胰腺导管腺癌和神经内分泌肿瘤患者组织,采用免疫组化半定量评分分析成纤维细胞活化蛋白(FAP)表达。结果发现全部40例朗格汉斯胰岛α细胞均表达FAP且评分为2,神经内分泌肿瘤与导管腺癌之间及导管腺癌是否接受新辅助化疗间均无差异。作者认为该表达预计不影响FAP靶向示踪剂的诊断准确性,但治疗场景下需进一步阐明FAPI放射性配体对胰岛功能的影响。

要点

  • 全部40例患者的朗格汉斯胰岛α细胞均表达FAP,半定量评分均为2分。
  • 神经内分泌肿瘤与导管腺癌之间FAP表达未见差异。
  • 导管腺癌患者无论是否接受新辅助化疗,FAP表达未见差异。

核心结论

  • 胰腺朗格汉斯胰岛α细胞正常表达FAP。
  • 作者认为该表达预计不影响FAP靶向示踪剂的诊断准确性。
  • 在治疗场景下,作者认为结果提示需更好地阐明FAPI放射性配体对朗格汉斯胰岛功能的影响。

研究设计与样本

  • 回顾性纳入2家机构共40例患者(每中心20例),其中胰腺导管腺癌20例、神经内分泌肿瘤20例。
  • 纳入标准为病理证实的胰腺导管腺癌和神经内分泌肿瘤、每中心每组10例、有石蜡包埋组织及临床病理记录。
  • 采用免疫组化分析及半定量视觉评分系统(0分为阴性;1分为阳性面积小于30%;2分为阳性面积大于30%)。
  • 按组织学类型(神经内分泌肿瘤n=20 vs 导管腺癌n=20)及导管腺癌组内既往治疗情况评估FAP表达。
  • 当地伦理委员会批准研究(编号INT 21/16,2016年1月28日)。

主要发现

  • 人群为24例男性和16例女性,中位年龄68岁,范围14-84岁。
  • 导管腺癌患者中8/20例接受过化疗。
  • 全部朗格汉斯胰岛(40/40)的胰腺α细胞均表达FAP,评分为2。
  • 神经内分泌肿瘤(20/20)与导管腺癌(20/20)之间FAP表达无差异。
  • 导管腺癌队列中,是否接受新辅助化疗者之间FAP表达无差异。

关键数值与推荐

  • 免疫组化半定量评分:0分为阴性染色;1分为阳性面积小于30%;2分为阳性面积大于30%。

临床怎么用

  • 作者认为胰腺朗格汉斯胰岛α细胞正常表达FAP预计不影响FAP靶向示踪剂的诊断准确性。
  • 在治疗场景下,作者认为结果提示需更好地阐明FAPI放射性配体对朗格汉斯胰岛功能的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiopharmaceuticals targeting fibroblast activation protein (FAP) alpha are increasingly studied for diagnostic and therapeutic applications. We discovered FAP expression at immunohistochemistry (IHC) in the alpha cells of the Langerhans insulae of few patients. Therefore, we planned an investigation aimed at describing FAP expression in the pancreas and discussing the implications for radioligand applications. METHODS: We retrospectively included 40 patients from 2 institutions (20 pts each) according to the following inclusion/exclusion criteria: (i) pathology proven pancreatic ductal adenocarcinoma and neuroendocrine tumors (NET), 10 pts per each group at each center; (ii) and availability of paraffin-embedded tissue; and (iii) clinical-pathological records. We performed IHC analysis and applied a semiquantitative visual scoring system (0, negative staining; 1, present in less than 30%; 2, present in more than 30% of the area). FAP expression was assessed according to histology-NET (n = 20) vs ductal adenocarcinoma (n = 20)-and to previous treatments within the adenocarcinoma group. The local ethics committee approved the study (No. INT 21/16, 28 January 2016). RESULTS: The population consisted of 24 males and 16 females, with a median age of 68 and a range of 14-84 years; 8/20 adenocarcinoma patients received chemotherapy. In all the Langerhans insulae (40/40), pancreatic alpha cells were found to express FAP, with a score of 2. No difference was found among NET (20/20) and adenocarcinoma (20/20), nor according to neoadjuvant chemotherapy in the adenocarcinoma cohort (received or not received). CONCLUSION: Pancreatic Langerhans islet alpha cells normally express FAP. This is not expected to influence the diagnostic accuracy of FAP-targeting tracers. In the therapeutic setting, our results suggest the need to better elucidate FAPI radioligands' effects on the Langerhans insulae function.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kirienko M, Centonze G, Sabella G, et al. FAP expression in alpha cells of Langherhans insulae-implications for FAPI radiopharmaceuticals' use. Eur J Nucl Med Mol Imaging. 2023. PMID: 37140668. doi:10.1007/s00259-023-06246-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。